Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

PURPOSE: In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In contrast, TP53 defects are not associated with resistance to the anti-CD52 monoclonal antibody alemtuzumab or methylprednisolone....

Full description

Bibliographic Details
Main Authors:	Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P
Format:	Journal article
Language:	English
Published:	2012

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Similar Items